Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Frontline experience with second generation covalent Bruton tyrosine kinase inhibitors for mantle cell lymphoma: A single center experience

Luke Maillie, Stefan Barta, Jordan Carter, Michael Cook, Mitchell Hughes, Daniel Landsburg, Sunita Dwivedy Nasta, Marco Ruella, Stephen Schuster, Jakub Svoboda, Colin Thomas, Emily Tomasulo, Elise Chong

Blood (2025) 146 (Supplement 1): 7119.

https://doi.org/10.1182/blood-2025-7119

Published: 2025

Journal Articles

Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden

Blood (2025) 146 (Supplement 1): 560.

https://doi.org/10.1182/blood-2025-560

Published: 2025

Journal Articles

IL18-armored CAR T cells in patients with CLL/SLL and Richter's transformation after prior BTK inhibitor and venetoclax failure

Blood (2025) 146 (Supplement 1): 2394.

https://doi.org/10.1182/blood-2025-2394

Published: 2025

Journal Articles

Multicenter real-world outcomes in limited stage (LS) diffuse large B-cell lymphoma (DLBCL) treated with abbreviated immunochemotherapy

Blood (2025) 146 (Supplement 1): 471.

https://doi.org/10.1182/blood-2025-471

Published: 2025

Journal Articles

Outcomes of patients with dual primary T-cell and B-cell lymphoid malignancies

Zachary Hing, Colin Thomas, Stephen Schuster, Daniel Landsburg, Sunita Dwivedy Nasta, Jakub Svoboda, Jordan Carter, Emeline Chong, Nicole Altomare, Reem Karmali, Venkata Preetam Sandeep Kaduluri, Cole Sterling, Danielle Miller, Zachary Frosch, Stefan Barta

Blood (2025) 146 (Supplement 1): 5409.

https://doi.org/10.1182/blood-2025-5409

Published: 2025

Journal Articles

Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas

Blood (2025) 146 (Supplement 1): 1952.

https://doi.org/10.1182/blood-2025-1952

Published: 2025

Journal Articles

Duration of lymphopenia after CAR-T cell therapy is associated with increased risk of non-melanoma skin cancers and decreased survival

Emeline Chong, Megan Jones, Guido Ghilardi, Luca Paruzzo, Sunita Dwivedy Nasta, Stefan Barta, Jakub Svoboda, Elise Chong, Jordan Carter, Colin Thomas, Michael Cook, Emily Tomasulo, Marco Ruella, Daniel Landsburg, Stephen Schuster

Blood (2025) 146 (Supplement 1): 3728.

https://doi.org/10.1182/blood-2025-3728

Published: 2025

Journal Articles

Naive CD4+ at apheresis and disease control at infusion are associated with improved efficacy in second-line CAR T-cells

Blood (2025) 146 (Supplement 1): 2755.

https://doi.org/10.1182/blood-2025-2755

Published: 2025

Journal Articles

Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies

Blood (2025) 146 (Supplement 1): 5501.

https://doi.org/10.1182/blood-2025-5501

Published: 2025

Journal Articles

Risk factors for failure to complete step-up-dosing of bispecific antibody therapy for B-cell lymphomas

Michael Cook, Emeline Chong, Ava Clifford, Daniel Landsburg, Sunita Dwivedy Nasta, Elise Chong, Stefan Barta, Jakub Svoboda, Jordan Carter, Colin Thomas, Emily Tomasulo, Stephen Schuster

Blood (2025) 146 (Supplement 1): 5522.

https://doi.org/10.1182/blood-2025-5522

Published: 2025

Journal Articles

Title first‑in‑human Phase 1 dose‑finding study (VIPER 101) of dual‑population autologous CD5‑deleted anti-CD5 CAR‑T (Senza5 CART5) cells in Relapsed/Refractory T‑cell lymphomas

Stefan Barta, Stephen Schuster, Jakub Svoboda, Jordan Carter, Elise Chong, Daniel Landsburg, Sunita Dwivedy Nasta, Ruchi Patel, Joseph Fraietta, Colin Thomas, Omar Elghawy, Ran Reshef, Aditya Nimmagadda, Lavanya Peddada, Adam Snook, Nicholas Siciliano, Rosemary Mazanet, Marco Ruella

Blood (2025) 146 (Supplement 1): 4174.

https://doi.org/10.1182/blood-2025-4174

Published: 2025

Journal Articles

A multicenter real-world analysis of combined chemotherapy followed by consolidative radiation versus chemotherapy alone in the management of early-stage Hodgkin lymphoma – the HODGKIN25 study

Blood (2025) 146 (Supplement 1): 3617.

https://doi.org/10.1182/blood-2025-3617

Published: 2025

Journal Articles

Cardiovascular outcomes of patients transitioned from ibrutinib to an alternate bruton tyrosine kinase inhibitor for hypertension and/or cardiovascular adverse events

Emily Tomasulo, Emeline Chong, Evani Patel, James Rudolph, Yejin Andrea Kim, Marco Ruella, Alex Watts, Wei-Ting Hwang, Mitchell Hughes, Jakub Svoboda, Daniel Landsburg, Elise Chong, Sunita Dwivedy Nasta, Stefan Barta, Colin Thomas, Michael Cook, Jordan Carter, Michael Fradley, Stephen Schuster

Blood (2025) 146 (Supplement 1): 5680.

https://doi.org/10.1182/blood-2025-5680

Published: 2025

Journal Articles

A retrospective multi-center review of the safety and efficacy of bispecific T-cell engagers in the management of post-transplant lymphoproliferative disorder – the bite PTLD study

Nikita Dave, Imran Nizamuddin, Neha Mehta-Shah, Edd Ricker, Jennifer Amengual, Robert Baiocchi, Timothy Voorhees, Stefan Barta, Jordan Carter, Elise Chong, Michael Cook, Daniel Landsburg, Stephen Schuster, Colin Thomas, Emily Tomasulo, Jakub Svoboda, Sunita Dwivedy Nasta

Blood (2025) 146 (Supplement 1): 1963.

https://doi.org/10.1182/blood-2025-1963

Published: 2025

Journal Articles

Survival outcomes for newly diagnosed non-germinal center large B cell lymphoma patients treated with R-CHOP based on double expressor status and genomic features

Alyssa Klein, Sunita Dwivedy Nasta, Stefan Barta, Jordan Carter, Elise Chong, Jakub Svoboda, Stephen Schuster, Colin Thomas, Emily Tomasulo, Michael Cook, Michael Bowman, Robert Bowman, Daniel Landsburg

Blood (2025) 146 (Supplement 1): 1891.

https://doi.org/10.1182/blood-2025-1891

Published: 2025

Journal Articles

Outcomes in octo- and nonagenarians treated with mogamulizumab-based regimens for cutaneous T-cell lymphoma

Omar Elghawy, Colin Thomas, Daniel Gao, Jordan Carter, Daniel Landsburg, Jakub Svoboda, Elise Chong, Ellen Kim, Alain Rook, Jina Chung, Jennifer Villasenor-Park, Carmela Vittorio, John Plastaras, Michael Lariviere, Harper Hubbeling, Sunita Dwivedy Nasta, Stephen Schuster, Stefan Barta

Blood (2025) 146 (Supplement 1): 1856.

https://doi.org/10.1182/blood-2025-1856

Published: 2025

Journal Articles

Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease

Blood (2025) 146 (Supplement 1): 4543.

https://doi.org/10.1182/blood-2025-4543

Published: 2025

Journal Articles

Outcomes in Primary CNS Lymphoma: A Single Institution Experience from the Abramson Cancer Center at the University of Pennsylvania

Nikita Dave, Veronica Carvajal, Jordan Carter, Donald Edward Tsai, Stephen J. Schuster, James Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Daniel J. Landsburg, Sunita D. Nasta

Blood (2024) 144 (Supplement 1): 1699.

https://doi.org/10.1182/blood-2024-207781

Published: 2024

Journal Articles

CD5-Deleted Chimeric Antigen Receptor Cells (Senza5™ CART5) to Enhance Immunotherapy Against T-Cell Non-Hodgkin Lymphoma: A First-in-Human Phase I Clinical Trial

Blood (2024) 144 (Supplement 1): 7221.

https://doi.org/10.1182/blood-2024-201063

Published: 2024

Journal Articles

Clinical Activity of Tisagenlecleucel in Large B Cell Lymphomas According to the 5 th Edition of the Who Classification

Guido Ghilardi, Emeline R. Chong, Luca Paruzzo, Giulia Gabrielli, Sunita D. Nasta, Vrutti Patel, Eugenio Fardella, Daniel J. Landsburg, Jordan Carter, Colin Thomas, Stefan K. Barta, Elise A. Chong, Jakub Svoboda, Marco Ruella, Stephen J. Schuster

Blood (2024) 144 (Supplement 1): 1750.

https://doi.org/10.1182/blood-2024-206027

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Frontline experience with second generation covalent Bruton tyrosine kinase inhibitors for mantle cell lymphoma: A single center experience

Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden

IL18-armored CAR T cells in patients with CLL/SLL and Richter's transformation after prior BTK inhibitor and venetoclax failure

Multicenter real-world outcomes in limited stage (LS) diffuse large B-cell lymphoma (DLBCL) treated with abbreviated immunochemotherapy

Outcomes of patients with dual primary T-cell and B-cell lymphoid malignancies

Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas

Duration of lymphopenia after CAR-T cell therapy is associated with increased risk of non-melanoma skin cancers and decreased survival

Naive CD4+ at apheresis and disease control at infusion are associated with improved efficacy in second-line CAR T-cells

Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies

Risk factors for failure to complete step-up-dosing of bispecific antibody therapy for B-cell lymphomas

Title first‑in‑human Phase 1 dose‑finding study (VIPER 101) of dual‑population autologous CD5‑deleted anti-CD5 CAR‑T (Senza5 CART5) cells in Relapsed/Refractory T‑cell lymphomas

A multicenter real-world analysis of combined chemotherapy followed by consolidative radiation versus chemotherapy alone in the management of early-stage Hodgkin lymphoma – the HODGKIN25 study

Cardiovascular outcomes of patients transitioned from ibrutinib to an alternate bruton tyrosine kinase inhibitor for hypertension and/or cardiovascular adverse events

A retrospective multi-center review of the safety and efficacy of bispecific T-cell engagers in the management of post-transplant lymphoproliferative disorder – the bite PTLD study

Survival outcomes for newly diagnosed non-germinal center large B cell lymphoma patients treated with R-CHOP based on double expressor status and genomic features

Outcomes in octo- and nonagenarians treated with mogamulizumab-based regimens for cutaneous T-cell lymphoma

Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease

Outcomes in Primary CNS Lymphoma: A Single Institution Experience from the Abramson Cancer Center at the University of Pennsylvania

CD5-Deleted Chimeric Antigen Receptor Cells (Senza5™ CART5) to Enhance Immunotherapy Against T-Cell Non-Hodgkin Lymphoma: A First-in-Human Phase I Clinical Trial

Clinical Activity of Tisagenlecleucel in Large B Cell Lymphomas According to the 5 th Edition of the Who Classification

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only